NeoVirTech, in partnership with Imactiv-3D, the ImPACT team from the Cancer Research Center of Toulouse and the National Veterinary School of Toulouse, obtains funding from AAP France 2030 organized by the French Government and the Occitanie region for the development of an innovative theranostic platform for cancer virotherapy, in strong collaboration with CHU de Toulouse and Oncopole Claudius Régaud.

This program, called Perseverance, supported by Transgene, aims to accelerate the preclinical development of oncolytic viruses (OV), viruses modified and armed to specifically destroy cancer cells. The program is organized into different work tasks, involving the design of ANCHOR^TM autofluorescent VO candidates for in vivo monitoring of infection and replication of VOs, their production and validation. ANCHOR™ VOs are then used to perform a virogram on different cancer cell lines to achieve precise mapping of oncolytic activities. The VOs are then optimized and tested for their interaction with pre-existing treatments. Finally, ANCHOR^TM VOs are tested on organoids derived from patients tumors, the infection of which is analyzed by deep learning and AI processes, and tested on animal models (mouse/rabbit).

At the end of the program, Perseverance offers a clear vision of the efficiency of a given VO on the most relevant models and close to the patient, in order to accelerate their development and guide clinical and therapeutic decisions.

The program is open to any VO of interest, regardless of their stage of development. For more information: contact@neovirtech.com

What if we could combine our autofluorescent viruses with state of the art nebulization chambers to investigate airborne disinfection? What if we had the ability to measure and visualize if a room has been correctly decontaminated ? What if we could measure viral persistence following airborne dispersion. Well, we can. We are very proud to announce our strategical alliance with VirexpR, the leader in airborne disinfection testing in France. This collaboration will allow NeoVirTech to use VirexpR nebulization room (2,5 and 20m³) to disperse its autofluorescent virus and to measure the efficiency of air treatment devices using an imaged based readout. The alliance provides customer with a unique way to measure and visualize directly airborne disinfection efficiency and efficacy of respiratory protection for example. Contact us to know more : contact@neovirtech.com, contact@virexpr.fr

NeoVirTech (NVT) and BioImmunitas Ltd enter a long-term partnership to advance a human recombinant protein therapeutic platform from bench to bedside. BioImmunitas Ltd has developed a highly cost-efficient series of recombinant proteins which form the platform therapeutic agent. This highly innovative treatment has been shown to be efficacious in several different therapeutic areas. Their collaboration with NeoVirTech has seen BioImmunitas utilize NVT’s proprietary antiviral discovery platform to position its own therapeutic hRPP on the anti-viral market.

NeoVirTech SAS opens a new laboratory at the Toulouse Cancer Research Center (CRCT) to structure its anti-cancer programs towards the creation of a patient-oriented theranostics platform, and to promote drug development

VirHealth SAS and NeoVirTech SAS announce the creation of a strategical alliance to create one of the most advanced private virus disinfection platform in Europe.